bio-track-icon_chronicdisease
Description

With drug pipelines slimming down in the face of complex and costly Phase IIIs and investors weary of downstream market pressures, will the industry continue on its quest to find innovative solutions to Obesity and Diabetes? This panel session will explore the challenges of two highly correlated metabolic diseases, obesity and diabetes, and their potential solutions. The discussion will explore examples of current innovative drug programs that may be overcoming these obstacles, and where the current pipeline and ecosystem is falling short.

Session ID: 545029

Tags